C

China National Medicines Corp Ltd
SSE:600511

Watchlist Manager
China National Medicines Corp Ltd
SSE:600511
Watchlist
Price: 28.73 CNY -0.1%
Market Cap: ¥21.7B

China National Medicines Corp Ltd
Deferred Income Tax

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

China National Medicines Corp Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
C
China National Medicines Corp Ltd
SSE:600511
Deferred Income Tax
¥17.8m
CAGR 3-Years
-19%
CAGR 5-Years
-15%
CAGR 10-Years
24%
Sinopharm Group Co Ltd
HKEX:1099
Deferred Income Tax
¥565.2m
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
-2%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Deferred Income Tax
¥1.9B
CAGR 3-Years
23%
CAGR 5-Years
19%
CAGR 10-Years
17%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Deferred Income Tax
¥436.6m
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
34%
Huadong Medicine Co Ltd
SZSE:000963
Deferred Income Tax
¥196.7m
CAGR 3-Years
-1%
CAGR 5-Years
17%
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Deferred Income Tax
¥93.9m
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
1%
No Stocks Found

China National Medicines Corp Ltd
Glance View

Market Cap
21.7B CNY
Industry
Health Care

China National Medicines Corp Ltd., often known as Sinopharm Group's public face, is a leviathan in the realm of pharmaceutical distribution. Headquartered in Beijing, this company is deeply entrenched in the layers of China's healthcare system. Its operations are woven through a vast network that includes the wholesale and retail distribution of an extensive range of pharmaceutical products. The company prides itself on streamlining the supply chain, connecting pharmaceutical manufacturers directly with hospitals, clinics, and pharmacies. By leveraging its logistical expertise and expansive reach, Sinopharm ensures that essential medicines flow seamlessly from producers to end-users, maintaining the vital heartbeat of the healthcare industry across China. In addition to its core distribution business, China National Medicines Corp Ltd. delves into the realm of medical device distribution and other healthcare-related services, diversifying its revenue streams. A significant portion of its income comes from partnerships and agreements with international pharmaceutical behemoths, allowing it to import and distribute advanced medicines and technology within China. By capitalizing on these strategic alliances, the company not only bolsters its portfolio but also strengthens its market position. This symbiotic relationship with both domestic and global players underpins its financial performance, making China National Medicines not just a distributor but a pivotal gatekeeper in the evolving landscape of China's healthcare industry.

Intrinsic Value
47.08 CNY
Undervaluation 39%
Intrinsic Value
Price ¥28.73
C

See Also

What is China National Medicines Corp Ltd's Deferred Income Tax?
Deferred Income Tax
17.8m CNY

Based on the financial report for Dec 31, 2025, China National Medicines Corp Ltd's Deferred Income Tax amounts to 17.8m CNY.

What is China National Medicines Corp Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
24%

Over the last year, the Deferred Income Tax growth was -26%. The average annual Deferred Income Tax growth rates for China National Medicines Corp Ltd have been -19% over the past three years , -15% over the past five years , and 24% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett